[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol
[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol Basic information
- Product Name:
- [2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol
- Synonyms:
-
- Tetrabenazine metabolite A
- Tetrabenazine metabolite B
- 2H-Benzo[a]quinolizin-2-ol, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-, (2R,3R,11bR)-
- [2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol
- NBI-98782
- (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol
- Tetrabenazine Related Impurity 27 (2R, 3R, 11bR)
- Tetrabenazine Related Impurity 27
- CAS:
- 85081-18-1
- MF:
- C19H29NO3
- MW:
- 319.44
- Product Categories:
-
- Impurities & Metabolites
- Tetrabenazine
- Mol File:
- 85081-18-1.mol
More
Less
[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol Chemical Properties
- Melting point:
- 106-108 °C(Solv: hexane (110-54-3))
- Boiling point:
- 457.8±45.0 °C(Predicted)
- Density
- 1.13
- storage temp.
- Store at -20°C
- solubility
- DMSO : 33.33 mg/mL (104.34 mM; Need ultrasonic)
- form
- Powder
- pka
- 14.75±0.40(Predicted)
- color
- White to off-white
More
Less
[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol Usage And Synthesis
Uses
(+)-α-Dihydrotetrabenazine is a potent inhibitor of vascular monoamine transporter 2 (VMAT2) and an agent of significant interest for therapeutic and molecular imaging applications.
Definition
ChEBI: (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol is a member of isoquinolines.
in vivo
NBI-98782 (10 mg/kg, p.o., daily for 7 days) decreases basal and APDs-induced monoamine efflux in both mPFC and dSTR in male C57BL/6J mice[1].
| Animal Model: | Male C57BL/6J mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | p.o., daily for 7 days |
| Result: | Decreased the efflux of DA, 5-HT and NE in mPFC, dSTR, HIP and NAC. Increased the efflux of DOPAC, HVA, and 5-HIAA in mPFC, dSTR, HIP and NAC. Decreased in cortical DA and DOPAC as well as striatal DA, 5-HT and NE efflux combinated with haloperidol (HY-14538, 0.5 mg/kg, i.p.). Decreased cortical Glu and striatal ACh, DA and GABA efflux combinated with Clozapine (HY-14539, 10 mg/kg, i.p.). Reduced PCP-induced increase in LMA between various time points. Suppressed clozapine-, olanzapine- and risperidone-induced DA efflux in both mPFC and dSTR, and ACh efflux in mPFC. |
[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-olSupplier
Jiangsu Vcare PharmaTech Co., Ltd.
- Tel
- 025-58741518 13327700685
- sales@vcarepharmatech.com
Daicel Chiral Technologies (China)CO.,LTD
- Tel
- 021-50460086-9 15921403865
- han_yajun@dctc.daicel.com
Nanjing Norris-Pharm Technology Co., Ltd
- Tel
- 18652989687
- sales@norris-pharm.com
Haoyuan Chemexpress Co., Ltd.
- Tel
- 021-58950125
- info@chemexpress.com
MedChemexpress LLC
- Tel
- 021-58955995
- sales@medchemexpress.cn